SCHEMBL1374076

SCHEMBL1374076

NC(=O)CC(NCCCO)C(N)=O

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ECE1 P42892 2/20 0.36
PTGS1 P23219 1/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1374080 1.00 ECE1 (0.36) ECE1PTGS1KCNH2
SCHEMBL3229885 0.92 TDP1 (0.36) ECE1
SCHEMBL3441239 0.88 ECE1 (0.38) ECE1
SCHEMBL1221420 0.88 ECE1 (0.38) ECE1
SCHEMBL1880686 0.86 CAMK2A (0.33) PTGS1KCNH2
SCHEMBL8424379 0.86 CAMK2A (0.33) PTGS1KCNH2
SCHEMBL4871139 0.86 ECE1 (0.39) ECE1
SCHEMBL29697562 0.82 ALOX15 (0.44) ECE1
SCHEMBL30885854 0.81 MAOA (0.48) ECE1
SCHEMBL8364638 0.81 ECE1 (0.34) ECE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8907045-B2 Biocompatible adhesive polymers EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2014-12-09 US claimed
US-8691284-B2 Fluorinated block co-polymers EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2014-04-08 US claimed
US-20140041802-A1 BIOCOMPATIBLE ADHESIVE POLYMERS EMPIRE TECHNOLOGY DEVELOPMENT LLC 2014-02-13 US claimed
WO-2013151537-A1 BIOCOMPATIBLE ADHESIVE POLYMERS EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2013-10-10 WO claimed
US-20130011487-A1 FLUORINATED BLOCK CO-POLYMERS EMPIRE TECHNOLOGY DEVELOPMENT LLC 2013-01-10 US claimed
WO-2013006173-A1 FLUORINATED BLOCK CO-POLYMERS EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2013-01-10 WO claimed
US-20160263235-A1 PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF ANGIOCHEM INC (CA) 2016-09-15 US disclosed
US-8907045-B2 Biocompatible adhesive polymers EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2014-12-09 US disclosed
EP-2794663-A1 PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF Angiochem Inc. (CA) 2014-10-29 EP disclosed
US-8691284-B2 Fluorinated block co-polymers EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2014-04-08 US disclosed
US-20140041802-A1 BIOCOMPATIBLE ADHESIVE POLYMERS EMPIRE TECHNOLOGY DEVELOPMENT LLC 2014-02-13 US disclosed
WO-2013151537-A1 BIOCOMPATIBLE ADHESIVE POLYMERS EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2013-10-10 WO disclosed
US-20130011487-A1 FLUORINATED BLOCK CO-POLYMERS EMPIRE TECHNOLOGY DEVELOPMENT LLC 2013-01-10 US disclosed
WO-2013006173-A1 FLUORINATED BLOCK CO-POLYMERS EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2013-01-10 WO disclosed
US-20110288011-A1 PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF ANGIOCHEM INC. (CA) 2011-11-24 US disclosed
WO-2010063124-A1 PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF ANGIOCHEM INC. (CA) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160263235-A1 PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF VIP, SLC1A5, SLC47A1 ECE1 677/4885PTGS1 3954/4885KCNH2 3270/4885
US-20130011487-A1 FLUORINATED BLOCK CO-POLYMERS SLC1A5, FGB, SLC43A1 ECE1 4391/4885PTGS1 4143/4885KCNH2 4085/4885
US-20110288011-A1 PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF VIP, SLC1A5, SLC47A1 ECE1 677/4885PTGS1 3954/4885KCNH2 3270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.